Ormco Unveils A Refreshed Brand Identity While Staying True to Core Values

With over 60 years of distinguished history in providing the orthodontic community with a breadth of high-quality, innovative products, solutions, and education, Ormco announces a brand refresh inspired by its recommitment as an innovative partner to the orthodontic community. With a continual dedication to partnership, investment in doctor-inspired innovation, and greater clinical freedom, the company will share its new company tagline, “Driving the future of orthodontics, together” along with the unveiling of a visually refreshed brand identity at this year’s American Association of Orthodontists (AAO) in Chicago, Illinois April 21-24, 2023.

Initial elements of Ormco’s brand refresh include:

New Company Tagline: “Driving the future of orthodontics, together”

New Logo: As a prominent representation of the company and its dedication, the new logo incorporates “Together” as a recommitment to collaboration and doctor-inspired innovation.

New Brand Colors: Fresh new colors convey passion and bring to life Ormco’s commitment, dedication, innovation, and future-focused partnership for all orthodontic solutions.

“In the spirit of a brand refresh, we continue to recognize and respect the expertise of orthodontic specialists as well as their investment in advancing their education, building a vision for their practices, and growing their businesses, all while helping patients enjoy healthier beautiful smiles,” said Eric Conley, SVP Orthodontics for Envista. “The renewed commitment to our existing and new customers is to provide best-in-class products, doctor-inspired innovation, and clinical freedom by giving the flexibility to choose orthodontic solutions and preferences that best fit their practices,” he continued.

As part of its commitment to driving the future of orthodontics, Ormco continually invests in doctor-inspired innovations. Ormco has more than 1000 patents worldwide and invests millions annually in Research & Development to ensure its products continue to respond to the evolving needs of orthodontists and patients.

“By investing in innovation, Ormco is also investing in me. It’s a symbiotic partnership. We make Ormco better, and Ormco makes us better,” said Dr. Trevor Nichols of Frost Nichols Orthodontics.

“Ormco also invests in the success of orthodontists through industry-leading partnership,” said Dr. Stuart Frost of Frost Nichols Orthodontics. “As the single, trusted, and proven partner for orthodontic specialists, Ormco helps simplify vendor management so we can focus on growing our practice. We turn to Ormco as our one source for complete orthodontic needs, as well as robust educational offerings, a dedicated support team, marketing resources, a generous loyalty program, and expert-led events to keep us at the forefront of our profession,” Dr. Frost continued.

The significant investment in R&D has led to a number of industry-first and breakthrough products and features including:

  • The first true full expression system designed for faster and more precise finishing with the Damon Ultima™ System.1
  • The new Ultima™ Hook, the only repositionable hook.2
  • Proprietary ceramic bracket technology and advanced clear bracket design with Symetri™ Clear
  • TruRoot™ for Spark™ Clear Aligners that allow doctors to see actual roots in the treatment plan
  • Ormco’s new OrthoPulse® 2.0 light-powered treatment accelerator that applies low-intensity infrared technology for up to 50% faster treatment time3 and a 73% reduction in pain4

Along with the Damon Ultima System for self-ligation, Ormco’s portfolio includes the Spark TM Clear Aligner System, Titanium Orthos TM, Symetri TM Clear, AOA Lab, Mini Twin TM, and OrthoPulse® Light Accelerated OrthodonticsTM*. In addition, as part of the Envista family of companies, Ormco provides doctors with Dexis™ IS scanning solutions and Metrex™ infection prevention solutions. With a portfolio encompassing wire and bracket systems, clear aligners, light accelerated technologies, 2D and 3D imaging, infection prevention, custom appliances, and more — Ormco provides a full gamut of innovations that help doctors improve patients’ smiles by leveraging the future of orthodontics.

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.